Related Experiment Video
Updated: Jan 14, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Novel Therapeutics for Hepatocellular Carcinoma
Mohamed I Elsaid1, Ashish Manne2
1Division of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA; Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Cancer Control, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Advances in hepatocellular carcinoma (HCC) treatment, including immunotherapy and targeted therapies, are improving survival. Precision oncology and addressing access barriers mark a new era of personalized HCC care.
Area of Science:
- Hepatobiliary cancers
- Medical oncology
- Translational research
Background:
- Advanced hepatocellular carcinoma (HCC) treatment has seen significant evolution.
- Traditional therapies have limitations, necessitating novel approaches.
Purpose of the Study:
- To review recent therapeutic advancements in advanced HCC.
- To highlight emerging targets and precision medicine strategies.
- To emphasize the importance of equitable access to care.
Main Methods:
- Literature review of recent clinical trials and research findings.
- Analysis of novel immunotherapy combinations and targeted agents.
- Exploration of precision oncology tools like liquid biopsy and AI imaging.
Main Results:
- Immunotherapy combinations (atezolizumab-bevacizumab, ipilimumab-nivolumab, STRIDE) improve survival.
- Novel checkpoints (LAG-3, TIGIT, TIM-3) and targeted therapies (FGFR4, β-catenin) show promise.
- Metabolic pathway inhibitors (ferroptosis, GLS1, NRF2, YAP-TAZ) demonstrate synergistic potential.
Conclusions:
- The therapeutic landscape for advanced HCC is rapidly transforming.
- Personalized and targeted approaches are becoming standard of care.
- Ensuring global equity in HCC treatment access is crucial.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers